In one sequence (left), an antibody (monoclonal or polyclonal) against a specific protein is pre-immobilized onto an insoluble support, such as agarose or magnetic beads, and then incubated with a cell lysate containing the target protein. During the incubation period, gentle agitation of the ly...
Immunotherapy is a process in which the immune system of the cancer patients is stimulated so that it can work smarter and harder for attacking the cancer cells. Some times the immune system is recognizing the cancer but it is not able to wipe cancer off due to slow response. There are di...
This monoclonal antibody is among the newest drugs to be FDA-approved for treating postmenopausal osteoporosis. It blocks a protein called sclerostin, which controls bone turnover. The dual-acting type of osteoporosis medication helps build bone while reducing bone density loss. ...
Venetoclax (Venclexta) is a type of BCL-2 inhibitor. It's a pill taken once a day. It can be used alone or with a monoclonal antibody. You might have some side effects after taking this drug, such as: Low levels of certain white blood cells (neutropenia) ...
A monoclonal antibody to the 72 kDa heat shock protein and Western blot analysis were used to determine the induction, accumulation and turnover of hsp 72 ... J Ettin - 《Birth Defects Research Part A Clinical & Molecular Teratology》 被引量: 162发表: 1992年 Effects of calcium channel block...
Another promising candidate is the new cholesteryl ester transfer protein [CETP] inhibitor K-312 that also inhibits PCSK9 expression. K-312 has been shown to decrease PCSK9 expression in hepatocytes in a mechanism independent from CETP inhibition. Undoubtedly there are remaining challenges in getting...
Programmed death ligand 1 (PD-L1) and programmed death protein 1 (PD-1) are well known immune checkpoint targets for cancer. Several biologics have been approved by the Food and Drug Administration for the treatment of cancer including anti-PD-1 monoclonal antibodies (mAbs) (Keytruda, Opdivo,...
et al. Protein kinase Cα is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347–364 (2013). Article CAS PubMed PubMed Central Google Scholar Celia-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human ...
AMG133 (subcutaneous, every 4 weeks) is a monoclonal antibody that was designed to antagonise the GIP receptor and is also linked to two modified GLP-1 peptides that activate the GLP-1 receptor [58]. Results from a phase 1 trial have supported further clinical evaluation with a dose-depende...
- "Target-based drugs": refers to drugs whose discovery process is largely dependent on observing the effect of a molecule on a protein. - "Phenotype-based drugs": refers to those drugs whose discovery process relies primarily on observing the effect of a molecule on the phenotype of an orga...